In a case with billions of dollars at stake, McDermott Will & Emery partners William G. Gaede III and Sarah C. Columbia won a rare post-trial ruling for Amgen Inc. that booted a rival’s drug from the market.
The Jan. 5 order granted the attorneys’ motion for a permanent injunction blocking Sanofi and Regeneron Pharmaceuticals Inc. from selling Praluent, a biological drug used to treat high LDL cholesterol, for the next 12 years. Just days earlier, Gaede and Columbia had staved off the defendants’ bid to throw out a March 2016 verdict upholding the validity of two patents Amgen held for its own biologic Rapatha.
